Q3 EPS Forecast for Soleno Therapeutics Boosted by Analyst

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Investment analysts at Lifesci Capital raised their Q3 2026 earnings per share estimates for shares of Soleno Therapeutics in a research note issued on Wednesday, November 5th. Lifesci Capital analyst K. Dellorusso now anticipates that the company will post earnings of $0.72 per share for the quarter, up from their prior estimate of $0.63. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q4 2026 earnings at $0.89 EPS.

A number of other equities analysts have also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Wednesday, October 8th. Robert W. Baird set a $121.00 price target on Soleno Therapeutics and gave the stock an “outperform” rating in a report on Friday, July 11th. The Goldman Sachs Group set a $125.00 price target on Soleno Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 7th. Guggenheim restated a “buy” rating and issued a $106.00 price target on shares of Soleno Therapeutics in a report on Wednesday, August 27th. Finally, Wall Street Zen upgraded Soleno Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 26th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Soleno Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $114.50.

Soleno Therapeutics Stock Down 26.6%

Shares of NASDAQ:SLNO opened at $46.87 on Thursday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 15.01 and a current ratio of 15.13. Soleno Therapeutics has a 1 year low of $41.50 and a 1 year high of $90.32. The stock has a market capitalization of $2.49 billion, a P/E ratio of -11.32 and a beta of -2.92. The stock has a 50-day simple moving average of $63.20 and a 200-day simple moving average of $73.27.

Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Tuesday, November 4th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.39. The firm had revenue of $66.02 million for the quarter, compared to analysts’ expectations of $47.46 million.

Hedge Funds Weigh In On Soleno Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Profund Advisors LLC boosted its stake in shares of Soleno Therapeutics by 95.2% during the 3rd quarter. Profund Advisors LLC now owns 19,839 shares of the company’s stock valued at $1,341,000 after buying an additional 9,677 shares during the last quarter. Oppenheimer & Co. Inc. boosted its stake in shares of Soleno Therapeutics by 172.2% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 8,848 shares of the company’s stock valued at $598,000 after buying an additional 5,598 shares during the last quarter. Bessemer Group Inc. boosted its stake in shares of Soleno Therapeutics by 2,170.0% during the 3rd quarter. Bessemer Group Inc. now owns 1,362 shares of the company’s stock valued at $92,000 after buying an additional 1,302 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Soleno Therapeutics by 35.1% during the 3rd quarter. Envestnet Asset Management Inc. now owns 7,925 shares of the company’s stock valued at $536,000 after buying an additional 2,059 shares during the last quarter. Finally, Jackson Creek Investment Advisors LLC purchased a new position in shares of Soleno Therapeutics during the 3rd quarter valued at approximately $1,028,000. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.